Esoteric Testing Market (By Type: Infectious Diseases Testing, Endocrinology Testing, Oncology Testing, Genetics Testing, Toxicology Testing, Immunology Testing, Neurology Testing, Other Testing; By Technology: Chemiluminescence Immunoassay, Enzyme-Linked Immunosorbent Assay, Mass Spectrometry, Real-Time PCR, DNA Sequencing, Flow Cytometry, Other Technologies; By End User) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023-2032
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Esoteric Testing Market
5.1. COVID-19 Landscape: Esoteric Testing Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Esoteric Testing Market, By Type
8.1. Esoteric Testing Market, by Type, 2023 2032
8.1.1 Infectious Diseases Testing
8.1.1.1. Market Revenue and Forecast (2020 2032)
8.1.2. Endocrinology Testing
8.1.2.1. Market Revenue and Forecast (2020 2032)
8.1.3. Oncology Testing
8.1.3.1. Market Revenue and Forecast (2020 2032)
8.1.4. Genetics Testing
8.1.4.1. Market Revenue and Forecast (2020 2032)
8.1.5. Toxicology Testing
8.1.5.1. Market Revenue and Forecast (2020 2032)
8.1.6. Immunology Testing
8.1.6.1. Market Revenue and Forecast (2020 2032)
8.1.7. Neurology Testing
8.1.7.1. Market Revenue and Forecast (2020 2032)
8.1.8. Other Testing
8.1.8.1. Market Revenue and Forecast (2020 2032)
Chapter 9. Global Esoteric Testing Market, By Technology
9.1. Esoteric Testing Market, by Technology, 2023 2032
9.1.1. Chemiluminescence Immunoassay
9.1.1.1. Market Revenue and Forecast (2020 2032)
9.1.2. Enzyme-Linked Immunosorbent Assay
9.1.2.1. Market Revenue and Forecast (2020 2032)
9.1.3. Mass Spectrometry
9.1.3.1. Market Revenue and Forecast (2020 2032)
9.1.4. Real-Time PCR
9.1.4.1. Market Revenue and Forecast (2020 2032)
9.1.5. DNA Sequencing
9.1.5.1. Market Revenue and Forecast (2020 2032)
9.1.6. Flow Cytometry
9.1.6.1. Market Revenue and Forecast (2020 2032)
9.1.7. Other Technologies
9.1.7.1. Market Revenue and Forecast (2020 2032)
Chapter 10. Global Esoteric Testing Market, By End User
10.1. Esoteric Testing Market, by End User, 2023 2032
10.1.1. Independent & Reference Laboratories
10.1.1.1. Market Revenue and Forecast (2020 2032)
10.1.2. Hospital-Based Laboratories
10.1.2.1. Market Revenue and Forecast (2020 2032)
Chapter 11. Global Esoteric Testing Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Type (2020 2032)
11.1.2. Market Revenue and Forecast, by Technology (2020 2032)
11.1.3. Market Revenue and Forecast, by End User (2020 2032)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Type (2020 2032)
11.1.4.2. Market Revenue and Forecast, by Technology (2020 2032)
11.1.4.3. Market Revenue and Forecast, by End User (2020 2032)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Type (2020 2032)
11.1.5.2. Market Revenue and Forecast, by Technology (2020 2032)
11.1.5.3. Market Revenue and Forecast, by End User (2020 2032)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Type (2020 2032)
11.2.2. Market Revenue and Forecast, by Technology (2020 2032)
11.2.3. Market Revenue and Forecast, by End User (2020 2032)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Type (2020 2032)
11.2.4.2. Market Revenue and Forecast, by Technology (2020 2032)
11.2.4.3. Market Revenue and Forecast, by End User (2020 2032)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Type (2020 2032)
11.2.5.2. Market Revenue and Forecast, by Technology (2020 2032)
11.2.5.3. Market Revenue and Forecast, by End User (2020 2032)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Type (2020 2032)
11.2.6.2. Market Revenue and Forecast, by Technology (2020 2032)
11.2.6.3. Market Revenue and Forecast, by End User (2020 2032)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Type (2020 2032)
11.2.7.2. Market Revenue and Forecast, by Technology (2020 2032)
11.2.7.3. Market Revenue and Forecast, by End User (2020 2032)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Type (2020 2032)
11.3.2. Market Revenue and Forecast, by Technology (2020 2032)
11.3.3. Market Revenue and Forecast, by End User (2020 2032)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Type (2020 2032)
11.3.4.2. Market Revenue and Forecast, by Technology (2020 2032)
11.3.4.3. Market Revenue and Forecast, by End User (2020 2032)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Type (2020 2032)
11.3.5.2. Market Revenue and Forecast, by Technology (2020 2032)
11.3.5.3. Market Revenue and Forecast, by End User (2020 2032)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Type (2020 2032)
11.3.6.2. Market Revenue and Forecast, by Technology (2020 2032)
11.3.6.3. Market Revenue and Forecast, by End User (2020 2032)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Type (2020 2032)
11.3.7.2. Market Revenue and Forecast, by Technology (2020 2032)
11.3.7.3. Market Revenue and Forecast, by End User (2020 2032)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Type (2020 2032)
11.4.2. Market Revenue and Forecast, by Technology (2020 2032)
11.4.3. Market Revenue and Forecast, by End User (2020 2032)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Type (2020 2032)
11.4.4.2. Market Revenue and Forecast, by Technology (2020 2032)
11.4.4.3. Market Revenue and Forecast, by End User (2020 2032)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Type (2020 2032)
11.4.5.2. Market Revenue and Forecast, by Technology (2020 2032)
11.4.5.3. Market Revenue and Forecast, by End User (2020 2032)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Type (2020 2032)
11.4.6.2. Market Revenue and Forecast, by Technology (2020 2032)
11.4.6.3. Market Revenue and Forecast, by End User (2020 2032)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Type (2020 2032)
11.4.7.2. Market Revenue and Forecast, by Technology (2020 2032)
11.4.7.3. Market Revenue and Forecast, by End User (2020 2032)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Type (2020 2032)
11.5.2. Market Revenue and Forecast, by Technology (2020 2032)
11.5.3. Market Revenue and Forecast, by End User (2020 2032)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Type (2020 2032)
11.5.4.2. Market Revenue and Forecast, by Technology (2020 2032)
11.5.4.3. Market Revenue and Forecast, by End User (2020 2032)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Type (2020 2032)
11.5.5.2. Market Revenue and Forecast, by Technology (2020 2032)
11.5.5.3. Market Revenue and Forecast, by End User (2020 2032)
Chapter 12. Company Profiles
12.1. ACM Global Laboratories (US)
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. ARUP Laboratories (US).
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Baylor Esoteric and Molecular Laboratory (US)
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. BioAgilytix Labs (US)
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. BP Diagnostic Centre SDN BHD (Malaysia)
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. BUHLMANN Diagnostics Corp (BDC, US)
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Cerba Xpert (Belgium)
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Eurofins Scientific (Luxembourg)
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Flow Health (US)
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Foundation Medicine (US)
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample